All In Biotech

NDA 021392 · Bausch

Cardizem La

Diltiazem Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Apr 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Feb 6, 2003

Approved uses

2

Original approval plus efficacy supplements

Registered trials

127

21 Phase 3, 6 recruiting

FAERS reports

12,237

10,144 serious, 2,820 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 11, 2025.

CARDIZEM LA is a nondihydropyridine calcium channel blocker indicated for: • treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It can be used alone or in combination with other antihypertensives. ( 1.1 ) • improving exercise tolerance in patients with chronic stable angina. ( 1.2 ) 1.1 Hypertension CARDIZEM ® LA is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome...

Mechanism: The therapeutic effects of diltiazem are believed to be related to its ability to inhibit the cellular influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscle. Hypertension: Diltiazem produces its antihypertensive effect primarily by relaxation of vascular smooth muscle and the resultant decrease in peripheral vascular resistance. The magnitude of blood pressure reduction is related to the degree of hypertension; thus hypertensive individuals experience an antihypertensive effect, whereas there is only a modest fall in blood pressure in normotensives....

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • CARDIZEM LA · DILTIAZEM HYDROCHLORIDE 120MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • CARDIZEM LA · DILTIAZEM HYDROCHLORIDE 420MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • CARDIZEM LA · DILTIAZEM HYDROCHLORIDE 300MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • CARDIZEM LA · DILTIAZEM HYDROCHLORIDE 180MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • CARDIZEM LA · DILTIAZEM HYDROCHLORIDE 360MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • CARDIZEM LA · DILTIAZEM HYDROCHLORIDE 240MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Diltiazem" as an intervention, any sponsor and status, largest first.

All 127 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea1,394
  • pain1,244
  • fatigue1,212
  • fall1,078
  • diarrhoea949
  • arthralgia940
  • headache938
  • dizziness930
  • nausea914
  • pruritus887
  • drug ineffective886
  • hypotension856

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004398
2005412
2006264
2007193
2008207
2009201
2010243
2011224
2012344
2013306
2014248
2015299
2016358
2017353
2018358
2019390
2020541
2021895
20221,440
20231,117
20241,353
20251,308
2026785

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cardizem La (Diltiazem HCl)

2024 spending

$682K

Beneficiaries

1,037

2,968 claims

Per beneficiary

$657

$3.65 per unit

View as table
YearSpending
2020$4,591,387
2021$4,368,406
2022$4,072,302
2023$2,461,645
2024$681,664

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,211 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.